Kura Oncology to Participate in Cantor Global Healthcare Conference
Rhea-AI Summary
Kura Oncology (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, has announced its participation in the upcoming Cantor Global Healthcare Conference in New York. The company's President and CEO, Troy Wilson, Ph.D., J.D., is set to take part in a fireside chat on September 17, 2024, at 1:20 p.m. ET / 10:20 a.m. PT.
Interested parties can access a live audio webcast of the fireside chat through the investor section of Kura's website at www.kuraoncology.com. An archived replay will also be available after the live event concludes. This conference participation provides an opportunity for Kura Oncology to showcase its progress and engage with the healthcare investment community.
Positive
- None.
Negative
- None.
SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the upcoming Cantor Global Healthcare Conference being held in New York. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a fireside chat at 1:20 p.m. ET / 10:20 a.m. PT on September 17, 2024.
A live audio webcast of the fireside chat will be available in the investor section of Kura’s website at www.kuraoncology.com with an archived replay available following the live event.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib, a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction, has received Breakthrough Therapy Designation for the treatment of relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML). Kura has completed enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML (KOMET-001). The Company is also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. Kura is evaluating KO-2806, a next-generation farnesyl transferase inhibitor (FTI), in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies (FIT-001). Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma (KURRENT-HN). For additional information, please visit Kura’s website at www.kuraoncology.com and follow us on X and LinkedIn.
Contacts
Investors:
Pete De Spain
Executive Vice President, Investor Relations &
Corporate Communications
(858) 500-8833
pete@kuraoncology.com
Media:
Cassidy McClain
Vice President
Inizio Evoke Comms
(619) 849-6009
cassidy.mcclain@inizioevoke.com
FAQ
When is Kura Oncology (KURA) participating in the Cantor Global Healthcare Conference?
What time is Troy Wilson's fireside chat at the Cantor Global Healthcare Conference?
How can investors access Kura Oncology's (KURA) fireside chat at the Cantor conference?
Will there be a replay available of Kura Oncology's (KURA) presentation at the Cantor Global Healthcare Conference?
